These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 8585757)

  • 1. Identification of a clinical isolate of HIV-1 with an isoleucine at position 82 of the protease which retains susceptibility to protease inhibitors.
    King RW; Winslow DL; Garber S; Scarnati HT; Bachelor L; Stack S; Otto MJ
    Antiviral Res; 1995 Sep; 28(1):13-24. PubMed ID: 8585757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and resistance patterns of MP-134 and MP-167, two novel inhibitors of HIV type 1 protease.
    Mo H; Markowitz M; Majer P; Burt SK; Gulnik SV; Suvorov LI; Erickson JW; Ho DD
    AIDS Res Hum Retroviruses; 1996 Jan; 12(1):55-61. PubMed ID: 8825619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered substrate specificity of drug-resistant human immunodeficiency virus type 1 protease.
    Dauber DS; Ziermann R; Parkin N; Maly DJ; Mahrus S; Harris JL; Ellman JA; Petropoulos C; Craik CS
    J Virol; 2002 Feb; 76(3):1359-68. PubMed ID: 11773410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor.
    Markowitz M; Mo H; Kempf DJ; Norbeck DW; Bhat TN; Erickson JW; Ho DD
    J Virol; 1995 Feb; 69(2):701-6. PubMed ID: 7815532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural insights into the South African HIV-1 subtype C protease: impact of hinge region dynamics and flap flexibility in drug resistance.
    Naicker P; Achilonu I; Fanucchi S; Fernandes M; Ibrahim MA; Dirr HW; Soliman ME; Sayed Y
    J Biomol Struct Dyn; 2013 Dec; 31(12):1370-80. PubMed ID: 23140382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 protease mutation 82M contributes to phenotypic resistance to protease inhibitors in subtype G.
    Palma AC; Covens K; Snoeck J; Vandamme AM; Camacho RJ; Van Laethem K
    J Antimicrob Chemother; 2012 May; 67(5):1075-9. PubMed ID: 22331593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor.
    Ho DD; Toyoshima T; Mo H; Kempf DJ; Norbeck D; Chen CM; Wideburg NE; Burt SK; Erickson JW; Singh MK
    J Virol; 1994 Mar; 68(3):2016-20. PubMed ID: 8107264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease.
    Otto MJ; Garber S; Winslow DL; Reid CD; Aldrich P; Jadhav PK; Patterson CE; Hodge CN; Cheng YS
    Proc Natl Acad Sci U S A; 1993 Aug; 90(16):7543-7. PubMed ID: 8356053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Limited sequence diversity of the HIV type 1 protease gene from clinical isolates and in vitro susceptibility to HIV protease inhibitors.
    Winslow DL; Stack S; King R; Scarnati H; Bincsik A; Otto MJ
    AIDS Res Hum Retroviruses; 1995 Jan; 11(1):107-13. PubMed ID: 7734183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 protease variants from 100-fold drug resistant clinical isolates: expression, purification, and crystallization.
    Vickrey JF; Logsdon BC; Proteasa G; Palmer S; Winters MA; Merigan TC; Kovari LC
    Protein Expr Purif; 2003 Mar; 28(1):165-72. PubMed ID: 12651121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteolytic activity of human immunodeficiency virus Vpr- and Vpx-protease fusion proteins.
    Wu X; Liu H; Xiao H; Kappes JC
    Virology; 1996 May; 219(1):307-13. PubMed ID: 8623547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic profiling of substrate binding response to multidrug-resistant mutations in HIV-1 protease: Implication for combating drug resistance.
    Lv Y; Li J; Fang J; Jiao X; Yan L; Shan B
    J Mol Graph Model; 2017 Jun; 74():83-88. PubMed ID: 28371730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV.
    Jadhav PK; Ala P; Woerner FJ; Chang CH; Garber SS; Anton ED; Bacheler LT
    J Med Chem; 1997 Jan; 40(2):181-91. PubMed ID: 9003516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 Protease, Reverse Transcriptase, and Integrase Variation.
    Rhee SY; Sankaran K; Varghese V; Winters MA; Hurt CB; Eron JJ; Parkin N; Holmes SP; Holodniy M; Shafer RW
    J Virol; 2016 Jul; 90(13):6058-6070. PubMed ID: 27099321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site.
    Yoshimura K; Kato R; Kavlick MF; Nguyen A; Maroun V; Maeda K; Hussain KA; Ghosh AK; Gulnik SV; Erickson JW; Mitsuya H
    J Virol; 2002 Feb; 76(3):1349-58. PubMed ID: 11773409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combinatorial design of nonsymmetrical cyclic urea inhibitors of aspartic protease of HIV-1.
    Frecer V; Burello E; Miertus S
    Bioorg Med Chem; 2005 Sep; 13(18):5492-501. PubMed ID: 16054372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. I36T↑T mutation in South African subtype C (C-SA) HIV-1 protease significantly alters protease-drug interactions.
    Maseko SB; Padayachee E; Govender T; Sayed Y; Kruger G; Maguire GEM; Lin J
    Biol Chem; 2017 Sep; 398(10):1109-1117. PubMed ID: 28525359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.
    Barrie KA; Perez EE; Lamers SL; Farmerie WG; Dunn BM; Sleasman JW; Goodenow MM
    Virology; 1996 May; 219(2):407-16. PubMed ID: 8638406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of drug-resistance in HIV-1 subtype C based on protease sequences from ART naive and first-line treatment failures in North India using genotypic and docking analysis.
    Toor JS; Sharma A; Kumar R; Gupta P; Garg P; Arora SK
    Antiviral Res; 2011 Nov; 92(2):213-8. PubMed ID: 21875619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance of HIV type 1 to proteinase inhibitor Ro 31-8959.
    Eberle J; Bechowsky B; Rose D; Hauser U; von der Helm K; Gürtler L; Nitschko H
    AIDS Res Hum Retroviruses; 1995 Jun; 11(6):671-6. PubMed ID: 7576926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.